| **Certainty assessment** | | | | | | | **№ of patients** | | **Effect** | | **Certainty** | **Importance** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **№ of studies** | **Study design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **oral** | **iv** | **Relative (95% CI)** | **Absolute (95% CI)** |
| **30-day rebleeding** | | | | | | | | | | | | |
| 10 | randomised trials | serious a | not serious | serious b | very serious c | none | 53/782 (6.8%) | 55/784 (7.0%) | **OR 0.96** (0.65 to 1.44) | **3 fewer per 1 000** (from 23 fewer to 28 more) | ⨁◯◯◯ VERY LOW | CRITICAL |
| **30-day mortality** | | | | | | | | | | | | |
| 10 | randomised trials | serious a | not serious | serious b | very serious c | none | 13/704 (1.8%) | 19/720 (2.6%) | **OR 0.70** (0.35 to 1.40) | **8 fewer per 1 000** (from 17 fewer to 10 more) | ⨁◯◯◯ VERY LOW | CRITICAL |
| **3-day rebleeding** | | | | | | | | | | | | |
| 7 | randomised trials | serious a | not serious | serious b | very serious c | none | 33/553 (6.0%) | 31/551 (5.6%) | **OR 1.07** (0.63 to 1.80) | **4 more per 1 000** (from 20 fewer to 41 more) | ⨁◯◯◯ VERY LOW | IMPORTANT |
| **Re-endoscopy** | | | | | | | | | | | | |
| 9 | randomised trials | serious a | not serious | serious b | very serious c | none | 50/603 (8.3%) | 56/578 (9.7%) | **OR 0.81** (0.52 to 1.28) | **17 fewer per 1 000** (from 44 fewer to 24 more) | ⨁◯◯◯ VERY LOW | IMPORTANT |
| **Further endoscopic therapy** | | | | | | | | | | | | |
| 7 | randomised trials | serious a | not serious | serious b | very serious c | none | 24/384 (6.3%) | 23/372 (6.2%) | **OR 1.04** (0.56 to 1.93) | **2 more per 1 000** (from 26 fewer to 51 more) | ⨁◯◯◯ VERY LOW | IMPORTANT |
| **Surgery** | | | | | | | | | | | | |
| 13 | randomised trials | serious a | not serious | serious b | very serious c | none | 8/870 (0.9%) | 9/881 (1.0%) | **OR 0.91** (0.40 to 2.07) | **1 fewer per 1 000** (from 6 fewer to 11 more) | ⨁◯◯◯ VERY LOW | IMPORTANT |
| **Blood transfusion** | | | | | | | | | | | | |
| 9 | randomised trials | serious a | not serious | serious b | very serious c | none | 586 | 579 | - | SMD **0.09 SD higher** (0.07 lower to 0.24 higher) | ⨁◯◯◯ VERY LOW | IMPORTANT |
| **Hospital stay** | | | | | | | | | | | | |
| 8 | randomised trials | serious a | serious d | serious b | very serious c | none | 567 | 560 | - | SMD **0.25 SD lower** (0.93 lower to 0.42 higher) | ⨁◯◯◯ VERY LOW | IMPORTANT |

**Supplementary Table 2 – GRADE – Results of the assessment by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method**

CI: Confidence interval; OR: Odds ratio; SMD: Standardised mean difference

Explanations

a. majority of included studies with some concerns or considerable risk of bias

b. use of different active substances and treatment regimes as interventions and comparators

c. optimal information size not reached; CI do include null effect and do include appreciable harm and/or benefit

d. significant heterogeneity present